High blood pressure and other known risk factors for stroke increase the risk of developing cognitive problems, a study funded by the National Institutes of Health has found.
The Scripps Research Institute has been awarded a $500,000 grant by the Michael J. Fox Foundation to study a pair of genetic mutations that could lead to a potential therapeutic target for Parkinson’s disease.
Pediatric neuroscientists at Oregon Health Science University Doernbecher Children’s Hospital used a high magnetic field strength MRI to reveal tiny white matter injuries in the developing brain previously undetectable using standard MRI.
In research at the University of Georgia, a cellular biologist and his colleagues have found that Hirano bodies may play a protective role in the progression of neurodegenerative diseases such as Alzheimer's.
The National Institutes of Health has renewed funding to the Indiana Alzheimer Disease Center at Indiana University School of Medicine for the fifth consecutive five-year term, awarding the center a grant of $9.1 million.
3D Biomatrix has developed protocols to precisely calibrate the Beckman Coulter Biomek FX laboratory automation workstation software for use with Perfecta3D hanging drop plates.
GBiosciences' Toothpick systems allow for the rapid screening of bacterial colonies by restriction enzyme digestion analysis or polymerase chain reaction, with the Plasmid Screening Toothpick and ToothpickPCR, respectively.
Battelle has enhanced its drug discovery and development services through a collaboration with Molecular Imaging Inc., a specialty provider of small-scale nonclinical in vivo multi-modality imaging services.
Irish drugmaker Warner Chilcott PLC said its board has authorized the redemption of up to $250 million in stock. The buybacks will be made through the open market or privately negotiated purchases with cash generated from operations.
Alkermes plc presented positive results from a long-term study of Vivitrol that showed sustained efficacy, as measured by the number of opioid-free urine screens, in patients who received Vivitrol.
QRxPharma Limited has received written acceptance from the United States Food and Drug Administration for review of the MoxDuo IR New Drug Application filed earlier this year.
Shares of Vertex Pharmaceuticals Inc. continued to slide on concerns that its hepatitis C drug Incivek, which was approved earlier this year, will be overtaken by newer drugs.
RNA drug developer Isis Pharmaceuticals Inc. reported a larger third-quarter loss. Isis said it lost $26.9 million, or 27 cents per share, over the three months ended Sept. 30.
Salix Pharmaceuticals Ltd. said it turned a profit in the third quarter on rising sales of its drug Xifaxan, used to treat diarrhea and certain neurological problems. Salix also agreed to buy privately held Oceana Therapeutics for $300 million in cash.
Bristol-Myers Squibb announced results from the Be?Low study, a Phase 3b clinical trial comparing Baraclude monotherapy with Baraclude plus tenofovir in treatment-naïve adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease.